197 related articles for article (PubMed ID: 30258198)
1. CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.
Worst TS; Weis CA; Stöhr R; Bertz S; Eckstein M; Otto W; Breyer J; Hartmann A; Bolenz C; Wirtz RM; Erben P
Sci Rep; 2018 Sep; 8(1):14383. PubMed ID: 30258198
[TBL] [Abstract][Full Text] [Related]
2. Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis.
de Jong JJ; Liu Y; Robertson AG; Seiler R; Groeneveld CS; van der Heijden MS; Wright JL; Douglas J; Dall'Era M; Crabb SJ; van Rhijn BWG; van Kessel KEM; Davicioni E; Castro MAA; Lotan Y; Zwarthoff EC; Black PC; Boormans JL; Gibb EA
Genome Med; 2019 Oct; 11(1):60. PubMed ID: 31619281
[TBL] [Abstract][Full Text] [Related]
3. Long noncoding RNA MIR31HG and its splice variants regulate proliferation and migration: prognostic implications for muscle invasive bladder cancer.
Wu S; Nitschke K; Worst TS; Fierek A; Weis CA; Eckstein M; Porubsky S; Kriegmair M; Erben P
J Exp Clin Cancer Res; 2020 Dec; 39(1):288. PubMed ID: 33334367
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of long non-coding RNA TUG1 predicts poor prognosis and promotes cancer cell proliferation and migration in high-grade muscle-invasive bladder cancer.
Iliev R; Kleinova R; Juracek J; Dolezel J; Ozanova Z; Fedorko M; Pacik D; Svoboda M; Stanik M; Slaby O
Tumour Biol; 2016 Oct; 37(10):13385-13390. PubMed ID: 27460088
[TBL] [Abstract][Full Text] [Related]
5. High IL-22RA1 gene expression is associated with poor outcome in muscle invasive bladder cancer.
Nitschke K; Worst TS; von Rhade SM; Thaqi B; Neuberger M; Wessels F; Weis CA; Porubsky S; Gaiser T; Kriegmair M; von Hardenberg J; Weidenbusch M; Erben P; Nuhn P
Urol Oncol; 2021 Aug; 39(8):499.e1-499.e8. PubMed ID: 34134925
[TBL] [Abstract][Full Text] [Related]
6. High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.
Breyer J; Wirtz RM; Erben P; Worst TS; Stoehr R; Eckstein M; Bertz S; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W;
Clin Genitourin Cancer; 2018 Aug; 16(4):248-256.e2. PubMed ID: 29525349
[TBL] [Abstract][Full Text] [Related]
7. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
[TBL] [Abstract][Full Text] [Related]
8. A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable.
van Kessel KE; van de Werken HJ; Lurkin I; Ziel-van der Made AC; Zwarthoff EC; Boormans JL
PLoS One; 2017; 12(3):e0174039. PubMed ID: 28319171
[TBL] [Abstract][Full Text] [Related]
9. Key signaling pathways in the muscle-invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment.
Kiselyov A; Bunimovich-Mendrazitsky S; Startsev V
Int J Cancer; 2016 Jun; 138(11):2562-9. PubMed ID: 26547270
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA expression profiles in muscle-invasive bladder cancer: identification of a four-microRNA signature associated with patient survival.
Xu Z; Yu YQ; Ge YZ; Zhu JG; Zhu M; Zhao YC; Xu LW; Yang XB; Geng LG; Dou QL; Jia RP
Tumour Biol; 2015 Sep; 36(10):8159-66. PubMed ID: 25990459
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer.
van der Vos KE; Vis DJ; Nevedomskaya E; Kim Y; Choi W; McConkey D; Wessels LFA; van Rhijn BWG; Zwart W; van der Heijden MS
Sci Rep; 2020 Jul; 10(1):10952. PubMed ID: 32616859
[TBL] [Abstract][Full Text] [Related]
12. Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer.
Avgeris M; Tsilimantou A; Levis PK; Rampias T; Papadimitriou MA; Panoutsopoulou K; Stravodimos K; Scorilas A
Carcinogenesis; 2019 Aug; 40(8):965-974. PubMed ID: 30815670
[TBL] [Abstract][Full Text] [Related]
13. Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma.
Baras AS; Gandhi N; Munari E; Faraj S; Shultz L; Marchionni L; Schoenberg M; Hahn N; Hoque MO; Berman D; Bivalacqua TJ; Netto G
PLoS One; 2015; 10(7):e0131245. PubMed ID: 26230923
[TBL] [Abstract][Full Text] [Related]
14. Chromobox homolog 8 is a predictor of muscle invasive bladder cancer and promotes cell proliferation by repressing the p53 pathway.
Yuan GJ; Chen X; Lu J; Feng ZH; Chen SL; Chen RX; Wei WS; Zhou FJ; Xie D
Cancer Sci; 2017 Nov; 108(11):2166-2175. PubMed ID: 28837252
[TBL] [Abstract][Full Text] [Related]
15. High expression of MMP14 is associated with progression and poor short-term prognosis in muscle-invasive bladder cancer.
Wang JF; Gong YQ; He YH; Ying WW; Li XS; Zhou XF; Zhou LQ
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6605-6615. PubMed ID: 32633349
[TBL] [Abstract][Full Text] [Related]
16. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer.
Pignot G; Cizeron-Clairac G; Vacher S; Susini A; Tozlu S; Vieillefond A; Zerbib M; Lidereau R; Debre B; Amsellem-Ouazana D; Bieche I
Int J Cancer; 2013 Jun; 132(11):2479-91. PubMed ID: 23169479
[TBL] [Abstract][Full Text] [Related]
17. Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer.
Teo MTW; Dyrskjøt L; Nsengimana J; Buchwald C; Snowden H; Morgan J; Jensen JB; Knowles MA; Taylor G; Barrett JH; Borre M; Ørntoft TF; Bishop DT; Kiltie AE
Ann Oncol; 2014 Apr; 25(4):877-883. PubMed ID: 24623370
[TBL] [Abstract][Full Text] [Related]
18. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
[TBL] [Abstract][Full Text] [Related]
19. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological Profiling of LC3B, an Autophagy Marker, and ESRRA (Estrogen-related Receptor-alpha) in Muscle-invasive Bladder Cancer.
Kim S; Lee AJ; Yeo MK; Na YG; Kim JY; Cho MJ; Kim JS; Jo EK; Kim JM
Anticancer Res; 2018 Apr; 38(4):2429-2437. PubMed ID: 29599373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
